Figures legends
Figure 1. Effect of overnight incubation with different
concentrations of benralizumab (A) and mepolizumab (B) on the AHR to
histamine CRCs in passively sensitized bronchi. ** P<0.01 and
*** P<0.001 vs. C+ (statistical analysis assessed by two-way
ANOVA); points represent the mean±SEM of n=5 bronchial tissue from
different subjects. AHR: airway hyperresponsiveness; C+: positive
control, passively sensitized bronchi; C-: negative control,
non-sensitized bronchi; CRC: concentration-response curve.
Figure 2. Inhibition of AHR to different concentrations of
histamine (EC50: A and D; EC70: B and E;
EC90: C and F) by overnight incubation with benralizumab
(A-C) and mepolizumab (D-F) in passively sensitized bronchi. Points
represent the mean±SEM of n=5 bronchial tissue from different subjects.
AHR: airway hyperresponsiveness; C+: positive control, passively
sensitized bronchi; C-: negative control, non-sensitized bronchi;
ECn: concentration inducing n% Emax;
Emax: maximal effect..
Figure 3. Effect of overnight incubation with different
concentrations of benralizumab (A) and mepolizumab (B) on the AHR to EFS
FRCs in passively sensitized bronchi. ** P<0.01 and ***
P<0.001 vs. C+ (statistical analysis assessed by two-way
ANOVA); points represent the mean±SEM of n=5 bronchial tissue from
different subjects. AHR: airway hyperresponsiveness; C+: positive
control, passively sensitized bronchi; C-: negative control,
non-sensitized bronchi; EFS: electrical field stimulation; FRC:
concentration-response curve.
Figure 4. Inhibition of AHR to different EFS frequencies
(EF50: A and D; EF70: B and E;
EF90: C and F) by overnight incubation with benralizumab
(A-C) and mepolizumab (D-F) in passively sensitized bronchi. Points
represent the mean±SEM of n=5 bronchial tissue from different subjects.
AHR: airway hyperresponsiveness; C+: positive control, passively
sensitized bronchi; C-: negative control, non-sensitized bronchi; CRC:
concentration-response curve; EFS: electrical field stimulation;
EFn: frequency inducing n% Emax;
Emax: maximal effect.
Figure 5 . Effect of overnight incubation with different
concentrations of benralizumab and mepolizumab on the AHR to QS of 0.5
mm in passively sensitized bronchi. # P<0.05 vs. C-; *
P<0.05 and ** P<0.01 vs. C+ (statistical analysis
assessed by Student’s t-test); bars represent the mean±SEM of n=5
bronchial tissue from different subjects. AHR: airway
hyperresponsiveness; C+: positive control, passively sensitized bronchi;
C-: negative control, non-sensitized bronchi; QS: quick stretch.
Figure 6. Effect of overnight incubation with different
concentrations of benralizumab and mepolizumab on the cAMP
concentrations in hyperresponsive bronchial tissue (A) and correlation
between the cAMP concentrations and the modulation of myogenic tone to
QS induced by the investigated treatments (B). ### P<0.001
vs. C-; * P<0.05, ** P<0.01, and ***
P<0.001 vs. C+ (statistical analysis assessed by Student’s
t-test); bars and points represent the mean±SEM of n=5 bronchial tissue
from different subjects. The colours of bars in A and the relative
treatments are consistent with the colours of points in B. C+: positive
control, passively sensitized bronchi; C-: negative control,
non-sensitized bronchi; cAMP: cyclic adenosine monophosphate; QS: quick
stretch.